Objectives: Rho and Rho-kinase play a critical role in the regulation of cellular functions such as proliferation and migration. To elucidate the molecular mechanisms that regulate cardiac function and cardiovascular remodeling, we determined whether the signaling pathway through Rho is involved in Dahl salt-sensitive hypertensive rats with congestive heart failure (CHF) using a specific Rho-kinase inhibitor, Y-27632. Methods: Y-27632 was administered from the left ventricular hypertrophy stage (11 weeks) to the CHF stage (18 weeks) for 7 weeks. The left ventricular end-systolic pressure-volume relationship (contractility: E ) was evaluated using a conductance es catheter. Results: Downregulated E in the CHF stage was significantly ameliorated by Y-27632 treatment. Increased RhoA protein, es Rho-kinase gene expression and myosin light chain phosphorylations in CHF rats were suppressed by Y-27632. Upregulated proto-oncogene c-fos gene expression in CHF rats was decreased by inhibiting Rho-kinase. In contrast, Y-27632 showed no effect on upregulated extracellular signal-regulated kinases (ERK) and p70S6 kinase phosphorylations, which were reported to be involved in protein synthesis. In the CHF stage, Y-27632 effectively inhibited vascular lesion formation such as medial thickness and perivascular fibrosis. Conclusions: These results suggest that differential activation of the Rho-Rho-kinase and the ERK-p70S6 kinase pathways may play a critical role in CHF, and the Rho-Rho-kinase pathway is involved in the pathogenesis of cardiac dysfunction and cardiovascular remodeling. Thus, inhibition of the Rho-kinase pathway may be at least a potential therapeutic strategy for CHF. 
. Introduction
mortality [1] . Therefore, identifying the pathway of molecular and cellular events that contribute to cardiovascular Congestive heart failure (CHF) begins with a cardiac remodeling is likely to provide novel targets for preventing insult such as long-standing hypertension, valvular disease, disease progression in heart failure. Extracellular signalischemic injury, or idiopathic myocardial dysfunction. The regulated kinases composed of p42ERK and p44ERK pathology of the end-stage failing human heart is char-(ERK1 / 2), are one main subgroup of mitogen-activated acterized by myocyte loss, myocardial collagen accumulaprotein kinases and are important mediators of the signaltion and collagen fibril disruption, remodeling of the transduction pathway responsible for cell differentiation extracellular matrix, and disorganization of the cardiac and growth. Recent evidence suggests that ERK in culmyofibrils. Moreover, this maladaptive remodeling contritured neonatal rat cardiac myocytes are rapidly activated butes to the diminished systolic performance as well as the by various extracellular stimuli, such as growth factors and decreased compliance of the failing human heart, and has other mitogens, and that they play a key role in cell growth been shown to be an important predictor of morbidity and and the regulation of various gene expressions [2] . On the other hand, p70S6 kinase, which leads to phosphorylation of the ribosomal S6 protein and increases the rate of translation of mRNAs containing a polypyrimidine tract, feeding with 8% NaCl diet and at 1-week intervals has been shown to activate in several cell types after either thereafter. In DS rats fed an 8% NaCl diet after the age of mitogenic stimulation, mechanical stretch, or integrin 6 weeks, a stage of concentric left ventricular hypertrophy receptor engagement. Therefore, p70S6 kinase could have at 11 weeks was followed by a distinct stage of left a key role on the load-induced hypertrophic growth ventricular failure with chamber dilatation at 18 weeks process [3] .
(DSCHF) [12, 13] . Fourteen 11-week-old DS hypertensive Rho and Rho-kinase, a downstream target protein of rats were randomly divided into two groups (DSCHF-V: small GTP-binding protein Rho, play crucial roles in n56, and DSCHF-R: n58). An osmotic minipump (model various cellular functions, and mediating cellular events 2ML4, Alzet) containing Y-27632 dissolved saline was such as changes in cell morphology, cell motility, focal implanted, and Y-27632 (DSCHF-R: 10 mg / kg per day, adhesions, and cytokinesis [4, 5] . The possibility that Rho subdepressor dose; WelFide) or vehicle (DSCHF-V) were is involved in vascular proliferation and migration is continuously infused from 11 to 18 weeks, and agesuggested by the involvement of Rho in the growth of matched DR rats (DR-C, 18 weeks, n56) fed the same nonvascular cells in response to heterotrimeric G protein diet served as a control group (Fig. 1) . receptor stimulation and in the migration of endothelial cells in response to mechanical strain or tyrosine kinase 2 .2. Left ventricular pressure-volume relation growth factors [6] . Indeed, the Rho and Rho-kinase pathway is involved in DNA synthesis and migration in
The chest was opened via a midline sternotomy, and the vascular smooth muscle cells (VSMCs) of rat aorta [7] . In pericardium was dissected to expose the heart. The left addition, cardiomyocyte hypertrophy and myofibrillar asventricular end-systolic pressure-volume relationship sembly are blocked by inhibitory mutants of Rho-kinase, (ESPVR) was modified for the conductance catheter which suggests a role for this Rho effector in cellular technique as described previously [14] . Briefly, the congrowth responses [8] . A recent study demonstrated that ductance catheter was inserted into the LV through the Rho-kinase may play a role in angiotensin II (Ang II)-apex and was pushed until the distal tip was placed into the induced hypertrophic changes of VSMCs [9] . Furthermore, ascending aorta along the longitudinal axis of the LV. A 3F in vivo study, Rho-kinase was involved in hypertensive catheter-tip micromanometer (SPR-524, Millar instruvascular diseases of spontaneously hypertensive rats (SHR) ments) was also inserted into the LV from the apex. To [10] . Therefore, inhibition of the Rho-kinase pathway may change the preload, a snare was placed around the inferior be useful in the treatment of arteriosclerotic cardiovascular vena cava. We recorded conductance volume and left diseases such as hypertensive heart failure. However, the ventricular pressure simultaneously during gradual inferior molecular mechanism responsible for the Rho-kinase vena cava occlusion. Electrical signals were digitized pathway in CHF remains to be determined. Recently, the through an analog-to-digital converter (AD12-8, Contec) at agent Y-27632 was shown to specifically inhibit these a sampling frequency of 1000 Hz with 12-bit resolution Rho-dependent kinases [11] . To elucidate the potential and stored on the personal computer (Dynabook SS 330, cardioprotective effects of a specific Rho-kinase inhibitor, Toshiba). The points of the ESPVR were determined using we evaluated the effects of Y-27632 on cardiac performan iterative technique reported previously [15] . In several ance and cardiovascular remodeling, and also clarified the consecutive pressure-volume loops, the points of each relation between the Rho-Rho-kinase and ERK-p70S6 cardiac cycle with a maximum pressure-to-volume ratio kinase pathways in the failing heart of Dahl salt-sensitive were first determined. Linear regression of these points (DS) hypertensive rats. with expression.
es es es 0
. Methods

.1. Animal model and experimental designs
All procedures were performed in accordance with international standards on animal welfare. Male inbred DS and Dahl salt-resistant (DR) rats, which were originally obtained from Brookhaven National Laboratories (Upton, NY, USA) were bred and supplied by Eisai, After weaning, the rats were fed a diet containing 0.3% NaCl until the age of 6 weeks. Thereafter, they were fed a diet containing 8% yielded estimates for the slope, or end-systolic elastance immunoblotting detection system (Amersham Life Sci-(E ), and volume-axis intercept (V ), where P and V ence) [12, 13, 19, 20] . Left ventricular ERK1 / 2, p70S6 kinase and MLC phosphorylations were measured as described in detail The RT-PCR was performed by the standard method previously [3, 21] . Briefly, using rabbit polyclonal with 1 mg of total RNA. First-strand cDNA was synphospho-ERK1 / 2, phospho-p70S6 kinase and goat polythesized with random primers and Molony murine clonal phospho-MLC antibody (New England Biolabs, leukemia virus reverse transcriptase (Promega). PCR amSanta Cruz, CA, USA) and anti-total ERK1 / 2, anti-total plification was then performed with synthetic gene-specific p70S6 kinase and anti-total MLC antibody (New England primers for Rho-kinase (sense primer, 59-GCA CAT GTA Biolabs) recognizing threonine-phosphorylated forms (ac-TGA AAA TGG ATG AAAC-39; antisense primer, 59-tive forms) of ERK1 / 2, p70S6 kinase and MLC, we CAT AAT TTT GCT GTA GGT TCC TAC AAGT-39), measured left ventricular phosphorylated ERK1 / 2, p70S6 c-fos (sense primer, 59-GGG ACA GCC TTT CCT ACT kinase and MLC proteins with Western blot analysis. Left ACC ATT-39; antisense primer, 59-CGC AAA AGT CCT ventricular protein extracts were boiled for 5 min in GTG TGT TGA-39), and eNOS (sense primer, 59-TCC Laemmli sample buffer, then electrophoresed on an SDS-AGT AAC ACA GAC AGT GCA-39; antisense primer, PAGE using 13% gels, and the separated proteins were 59-CAG GAA GTA AGT GAG AGC-39) using a DNA electrophoretically transferred to Hybond-PVDF mem-PCR kit (Perkin Elmer) for 30 cycles of denaturation at branes. Complete protein transfer to the membrane was 95 8C for 30 s, annealing at 55 8C for 30 s, and elongation ensured by staining the gels with Coomassie blue. The at 72 8C for 1 min. GAPDH was used as the housekeeping membrane was incubated with phospho-specific ERK1 / 2, gene. The reaction conditions were optimized to obtain p70S6 kinase and MLC antibody for 1 h at room temperareproducible and reliable amplification within the logarithture, washed four times with TBS-T, and then incubated mic phase of the reaction, as determined by preliminary with horseradish peroxidase-conjugated donkey anti-rabbit experiments. The reaction was linear to 35 cycles with use and goat immunoglobulin (Amersham Life Sciences). of the ethidium bromide detection method. The intensity of each band was quantified using a densitometer 2 .6. Histologic examination and evaluation of [12, 13, 16, 17] . cardiovascular remodeling
.4. Western blot analysis of RhoA and eNOS
Histological examination was studied as described in detail previously [12, 13, 16, 17, [19] [20] [21] . Briefly, excised LV was homogenized (25% w / v) in 10 mmol / l HEPES hearts were perfused with physiological saline solution buffer, pH 7.4, containing 320 mmol / l sucrose, 1 mmol / l containing adenosine 10 mg / kg and nitroglycerin 10 mg / EDTA, 1 mmol / l DTT, 10 mg / ml leupeptin, and 2 mg / ml kg and then with 6% formaldehyde solution via retrograde aprotinin at 0-4 8C with a polytron homogenizer. The infusion into the ascending aorta at a pressure of 90 homogenate was centrifuged at 3000 g for 5 min at 4 8C mmHg. The LV was separated from the right ventricle, the (eNOS), and then the supernatant was centrifuged at atria, and the great vessels, and cut into five pieces 100 000 g for 30 min to generate membrane and cytosolic perpendicular to the long axis. For light microscopy, 1.5-fractions as described previously (RhoA) [18] . Protein mm thick sections were cut using an ROM-380 microtome concentrations were determined with bovine serum al-(Yamato Kohki, Saitama, Japan). Paraffin slices from each bumin as a standard protein. Equal amounts of protein heart were mounted on glass slides and stained with from membrane and cytosolic fractions (RhoA) and the hematoxylin-eosin and Masson's trichrome stains. All other supernatant samples (eNOS) were loaded in each histopathological sections of each animal were examined lane of SDS-PAGE using 13 and 10% gels. The proteins using a 3CCD color video camera (DXC-930; Sony, in the gels were transferred electrophoretically to PVDF Tokyo, Japan) mounted on a standard microscope (BHS-F; 2 sheets for 1 h at 2 mA/cm (40 V, 300 mA, overnight). Olympus, Tokyo, Japan). Drawings of the limits of the The sheets were immunoblotted with an anti-RhoA and vessels were made on the screen of a multiscan color anti-eNOS antibody (Santa Cruz, Transduction Laboratorcomputer display (model CPD-17SF7; Sony) and then ies) in a buffer containing 10 mmol / l Tris-HCl, pH 7.5, digitized with a two-dimensional analysis system (Mac 100 mmol / l NaCl, 0.1% Tween 20, and 5% skim milk SCOPE; Mitani, Fukui, Japan) connected to a Macintosh followed by peroxidase-conjugated anti-mouse IgG (Amercomputer system (Power Macintosh G3; Apple Computer, sham Life Science Inc). The RhoA and eNOS proteins Cupertino, CA, USA). Histopathological findings of the transferred to the sheets were detected using the ECL myocardium and coronary arterioles were examined. We always measured the capillary density and cross-sectional surface area in the endocardium of the posterior portion of the left ventricular free wall. In this part of the heart, shrinkage was minimal and orientation of the myocardial fibers was similar from one heart to another. We analyzed five sites from each ventricle in all rats. To assess thickening of the coronary arterial wall and perivascular fibrosis, the transsectional images of the area of the total 4 2 small arteriolar lumen #10 mm were studied. The inner border of the lumen and the outer border of the tunica media were traced in each arterial image with hematoxylin-eosin staining at 3100 to 3400 magnification, and the areas encircled by the tracings were calculated. In quantification, non-round vessels resulting from oblique transsection or branching were excluded, and only round vessels were studied. The wall-to-lumen ratio (the area of the vessel wall divided by the area of the total blood vessel lumen) was determined. The area of fibrosis immediately surrounding blood vessels was calculated, and perivascular fibrosis was determined as the ratio of the area of fibrosis surrounding the vessel wall to the total area of the vessel.
To assess the area of myocardial fibrosis, the area of pathological collagen deposition was measured in the microscopic field of each Masson's trichrome-stained section. The ratio of the total area of fibrosis within the left ventricular myocardium to the total area of the left 
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Statistical analysis compared with DR-C, and significantly increased in All results are expressed as the mean6S.E.M. The mean DSCHF-R compared with DSCHF-V. The body-weightvalues were compared among the three groups using corrected left ventricular mass of the DSCHF-V was ANOVA followed by the Bonferroni test. Differences at significantly greater than that of the DR-C, and signifi-P,0.05 were considered statistically significant. Calculacantly attenuated in DSCHF-R compared with DSCHF-V tions, including those of derived values, and statistical after 7 weeks treatment with Y-27632. The body-weighttests, were performed using the appropriate software corrected lung and liver weight was significantly increased (STATVIEW-J 4.5, Abacus Concepts) and a Power Macintosh in DSCHF-V compared with the DR-C, and significantly computer system (G4, Apple Computer).
decreased in DSCHF-R compared with the DSCHF-V after 7 weeks treatment with Y-27632. 
. Results
.2. Left ventricular E , end-diastolic pressure, and
.1. Systemic hemodynamics, body weight, and organ end-systolic pressure in ESPVR weight
Left ventricular E in ESPVR was significantly lower in es Time-related changes in SBP among the three groups DSCHF-V than in DR-C (11786106 vs. 22236298 are shown in Fig. 2 . Before feeding with 8% NaCl diet, mmHg / ml, P,0.01), and significantly greater in DSCHF-SBP was 11563 mmHg in DR-C, 11864 mmHg in R than in DSCHF-V (37456276 mmHg / ml vs. DSCHF-V, DSCHF-V and 11664 mmHg in DSCHF-R. As shown in P,0.01) (Figs. 3 and 4A ). Left ventricular end-diastolic Table 1 , SBP in DSCHF-V and DSCHF-R was similar and pressure in ESPVR was significantly increased in DSCHFsignificantly higher than that in DR-C. Increased heart rate V compared with the DR-C (20.2961.36 vs. 4.8760.50 in DSCHF-V was significantly attenuated in DSCHF-R. mmHg, P,0.01), and significantly decreased in DSCHF-R Body weight in DSCHF-V was significantly decreased compared with the DSCHF-V (9.8960.37 mmHg vs. DSCHF-V, P,0.01) (Fig. 4B ). In ESPVR, left ventricular 3 .3. Involvement of RhoA and Rho-kinase expression end-systolic pressure in DSCHF-V and DSCHF-R was and activity in the failing heart similar and significantly higher than that in DR-C (DSCHF-V: 132.269.7, DSCHF-R: 137.069.3, vs. DR-C:
The levels of RhoA protein in the LV were 3.8-fold 92.569.4 mmHg, P,0.05, respectively).
(P,0.01) larger in DSCHF-V than in DR-C, and were 70% (P,0.01) lower in DSCHF-R than in DSCHF-V (Fig.  5A) . Expressions of Rho-kinase mRNA were 4.3-fold (P, 0.01) larger in DSCHF-V than in DR-C, and were 66% (P,0.01) lower in DSCHF-R than in DSCHF-V (Fig. 5B ).
In addition, to quantify the activity of Rho-kinase in failing heart, we performed Western blot analysis for phosphorylated MLC. The left ventricular phospho-MLC activity was 4.2-fold (P,0.01) larger in DSCHF-V than in DR-C, and 74% (P,0.01) lower in DSCHF-R than in DSCHF-V (Fig. 5C ). The levels of c-fos mRNA were 3.0-fold (P,0.01)
vs. DR-C; † †, P,0.01 vs. DSCHF-V.
larger in DSCHF-V than in DR-C, and were 59% (P, 0.01) lower in DSCHF-R than in DSCHF-V (Fig. 6A) .
.5. Relation between Rho-Rho-kinase and ERK-p70S6
ventricular phospho-ERK1 / 2 activities were significantly kinase pathway higher in DSCHF-V than in DR-C, and the phosphorylation of ERK1 / 2 activation was not inhibited by Y-27632 To evaluate the relation between the Rho-Rho-kinase (Fig. 6B) . Moreover, similarly cardiac phospho-p70S6 and ERK-p70S6 kinase pathways, we examined whether kinase activity was significantly increased in DSCHF-V the Rho-Rho-kinase pathway was involved in ERK1 / 2 compared with DR-C, and the phospho-p70S6 kinase and p70S6 kinase activities in the failing heart. The left activation was not inhibited by Y-27632 (Fig. 6C ).
Y-27632 treatment (Fig. 7B,D-F) . Compared with DR-C, myocardial fibrosis was significantly greater in DSCHF-V, and it was significantly less in DSCHF-R than in DSCHF-V (Fig. 7C) .
.7. Effect of Y-27632 on eNOS mRNA and protein levels
To evaluate the mechanisms of the beneficial effect of inhibiting the Rho-kinase pathway, expression of eNOS mRNA and protein was measured. Left ventricular eNOS mRNA levels were 57% (P,0.05) lower in DSCHF-V than in DR-C, and were 6.0-fold (P,0.01) larger in DSCHF-R than in DSCHF-V (Fig. 8A) . The levels of eNOS protein in the LV were 54% (P,0.05) lower in DSCHF-V than in DR-C, and were 4.2-fold (P,0.01) larger in DSCHF-R than in DSCHF-V (Fig. 8B ).
. Discussion
In the present study, we demonstrated that Rho and Rho-kinase pathway was involved in the pathogenesis of cardiac dysfunction and cardiovascular remodeling, and that inhibition of Rho-kinase plays a critical role in amelioration of the failing heart. The Rho-Rho-kinase and ERK-p70S6 kinase pathways may be independent of each other in the signaling of the failing heart. These results suggest that differential activation of the Rho-Rho-kinase and ERK-p70S6 kinase pathways may play a key role in the failing heart, and inhibiting the Rho-kinase pathway may be a useful therapeutic strategy for CHF (Fig. 9) .
The Rho and Rho-kinase pathway plays an important role in regulation of VSMCs contraction and other cellular functions such as proliferation and migration. In vitro studies, Kuwahara et al. [22] evaluated the Rho-ROCK pathway in endothelin-1 (ET-1) induced hypertrophic signals in cardiac myocytes. They suggested that Y-27632 significantly suppressed ET-1-induced hypertrophic re- mediate the stimulation of VSMC growth. Moreover, in vivo studies, Mukai et al. [10] examined the role of 3 .6. Effect of a Rho-kinase inhibition on cardiovascular Rho-kinase in functional and structural alterations of remodeling hypertensive blood vessels in SHR. They concluded that upregulation of Rho-kinase plays a key role in the pathoThe wall-to-lumen ratio was increased in DSCHF-V genesis of hypertensive vascular disease. Furthermore, compared with DR-C but was significantly decreased by Hisaoka et al. [24] showed that a G-protein-coupled 21 Y-27632 treatment (Fig. 7A,D-F) . The degrees of increase in myofilament Ca sensitivity mediated through perivascular fibrosis were significantly greater in DSCHFthe Rho-Rho-kinase system is heavily involved in the V than in DR-C, and was also significantly decreased by mechanism underlying the enhanced vasoconstriction ob- served in heart failure produced by chronic rapid pacing. c-fos gene was upregulated in failing heart, and also that These results suggest that Rho and Rho-kinase may be Y-27632 inhibited this gene expression. In cultured neonatinvolved in the pathogenesis of cardiac dysfunction and al rat myocytes, passive stretch stimulates the immediate cardiovascular remodeling [10, 24] . growth response of the induction of proto-oncogenes that Activation of ERK1 / 2 and p70S6 kinase has been is mediated by the autocrine release of Ang II [27] . In reported to be closely related to protein synthesis in addition, Kent et al. [28] has reported that load-induced VSMCs. We examined whether Rho-kinase might be c-fos expression was Ang II-dependent in quiescent adult involved in ERK-p70S6 kinase activation. Numaguchi et cardiocytes subjected to passive stretch. Recently, we have al. [25] reported that the Rho and Rho-kinase pathway demonstrated that left ventricular angiotensin-converting regulated mechanical stretch-induced ERK1 / 2 activation enzyme (ACE) mRNA expression was increased in in VSMCs. In contrast, in the present study, we observed DSCHF-V [17] . Therefore, c-fos gene expression may that Y-27632 showed no effect on phosphorylation of increase in failing heart stage. Moreover, Yamakawa et al. ERK-p70S6 kinase activities. Takeda et al. [26] demon- [9] showed that Rho-kinase is partially involved in Ang strated that inhibition of Rho-kinase Y-27632 did not affect II-induced c-fos gene expression in VSMCs. Furthermore, Ang II-induced ERK activation in VSMCs. In addition, Ueyama et al. [29] reported that activated RhoA stimulated Yamakawa et al. [9] reported that Y-27632 showed no c-fos gene expression in myocardial cells. These results effect on the ERK1 / 2 and p70S6 kinase phosphorylations suggested that Ang-II-induced expression of the c-fos gene induced by Ang II in VSMCs. These results suggested that expression might be mediated through activation of Rhothe Rho-Rho-kinase and ERK-p70S6 kinase pathways kinase. may be independent of each other in the signaling of the The agent Y-27632 has been shown to specifically failing heart. Thus, inhibiting the Rho-kinase pathway may inhibit Rho-dependent kinases (K 5 0.14 mM for i play a key role in CHF. p160ROCK: .1003 selectivity vs. protein kinase C, In the present study, we showed that expression of the cAMP-dependent protein kinase and MLC kinase) [11] . A new pyridine derivative, Y-27632, selectively inhibits 21 smooth-muscle contraction by inhibiting the Ca -sensitization mechanism. This compound inhibited smooth muscle contraction both in vitro and in vivo, as well as the formation of stress fibres and focal adhesions induced by p160ROCK in cultured cells. Therefore, Y-27632 is a valuable tool for investigating the functions of p160ROCK in vivo and its pathophysiological implications. As well as modulating smooth-muscle contraction, the Rho-kinase pathway may help to regulate integrin-mediated cell adhesion and motility, which could be critical in processes such as tumor-cell metastasis and immunoactivation. Thus, Y-27632 should be useful for investigating the role of p160ROCK in these processes and may be clinically important [11] . The mechanisms of the cardioprotective effect of inhibiting Rho-kinase is unknown. In the present study, we showed that expression of eNOS mRNA and protein was upregulated by inhibiting Rho-kinase. Laufs et al. [30] showed that the upregulation of eNOS expression by hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was mediated by inhibiting Rho GTPase. They suggested that Rho negatively regulated eNOS expression and that HMG-CoA reductase inhibitors upregulated eNOS expression by blocking Rho. These results suggest that the production of eNOS expression by inhibiting the Rho-Rho-kinase pathway may play a critical role in the cardioprotective effect of cardiac dysfunction and remodeling (Fig. 9) . addition, Sanbe et al. [32] reported that using transgenic mice overexpressing nonphoshorylatable regulatory MLC, 21 there was no shift of the myofibrillar Ca sensitivity after 21 treatment with MLC kinase, whereas the Ca sensitivity increased depending on the treatment with MLC kinase in nontransgenic mice. These transgenic mice also showed enlargement of cardiac chambers. They concluded that the phosphorylation of regulatory MLC appeared to play an important role in maintaining normal cardiac function. Moreover, Suematsu et al. [33] reported that a -adreno-1 ceptor-Gq signaling is upregulated in the failing myocar-21 dium to increase the myofibrillar Ca sensitivity mainly through the RhoA-Rho kinase pathway rather than 21 through the protein kinase C pathway. The increased Ca sensitivity by the upregulated Gq signaling may be one of the abnormal regulatory mechanisms of contractility in the failing heart. These results suggest that MLC phosphorylation may play a key role in maintaining cardiac performance and remodeling. The cardiac interstitium is composed of nonmyocyte cells and a structural protein network which plays a 
